Great Point Partners LLC raised its holdings in Kura Oncology Inc (NASDAQ:KURA) by 1.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,086,053 shares of the company’s stock after buying an additional 38,253 shares during the quarter. Kura Oncology accounts for about 4.3% of Great Point Partners LLC’s investment portfolio, making the stock its 10th largest position. Great Point Partners LLC owned about 6.81% of Kura Oncology worth $46,815,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in KURA. Marshall Wace LLP acquired a new stake in shares of Kura Oncology during the 1st quarter worth approximately $372,000. SG Americas Securities LLC acquired a new stake in Kura Oncology in the 2nd quarter valued at $137,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Kura Oncology by 599.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after buying an additional 2,420 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in Kura Oncology by 63.3% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 19,600 shares of the company’s stock valued at $388,000 after buying an additional 7,600 shares in the last quarter. Finally, Swiss National Bank boosted its stake in Kura Oncology by 36.1% in the 2nd quarter. Swiss National Bank now owns 61,400 shares of the company’s stock valued at $1,209,000 after buying an additional 16,300 shares in the last quarter. 88.72% of the stock is currently owned by hedge funds and other institutional investors.
KURA has been the subject of several research analyst reports. Cowen reiterated a “buy” rating on shares of Kura Oncology in a research report on Wednesday, November 6th. Wedbush reiterated a “positive” rating on shares of Kura Oncology in a research report on Wednesday, September 4th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price objective on shares of Kura Oncology in a research report on Thursday, September 5th. ValuEngine upgraded Kura Oncology from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Kura Oncology presently has a consensus rating of “Buy” and an average target price of $25.43.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, sell-side analysts forecast that Kura Oncology Inc will post -1.53 earnings per share for the current year.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Story: Analyzing a company’s cash flow statement
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.